Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.
Recovery
implementation
opioid agonist therapy
opioid use disorder
policy
recovery residence
Journal
The American journal of drug and alcohol abuse
ISSN: 1097-9891
Titre abrégé: Am J Drug Alcohol Abuse
Pays: England
ID NLM: 7502510
Informations de publication
Date de publication:
03 05 2020
03 05 2020
Historique:
pubmed:
25
2
2020
medline:
12
1
2021
entrez:
25
2
2020
Statut:
ppublish
Résumé
Full and partial opioid agonists and opioid antagonist medications play an important role in containing the opioid epidemic. However, these medications have not been used to their full extent. Recovery support services, such as recovery residences (RRs), also play a key role. RRs may increase an individual's recovery capital, facilitate social support for abstinence, and foster a sense of community among residents. These processes may be critical for individuals with opioid use disorder (OUD). In combination these two recovery pathways have the potential to enhance one another and improve outcomes among residents with OUD. Barriers to doing so have resulted in a limited supply of residences that can support residents using opioid agonist and antagonist medications. This perspective describes key interpersonal and structural barriers to medication use among individuals with an OUD seeking support from a recovery residence and discusses measures for reducing these barriers. These measures include workforce development to address stigma and attitudinal barriers and enhancing residence capability to ensure resident safety and reduce potential diversion. The perspective also highlights the need for additional research to facilitate the identification of best practices to improve outcomes among residents treated with medications living in recovery residences.
Identifiants
pubmed: 32091262
doi: 10.1080/00952990.2020.1719410
pmc: PMC7260098
mid: NIHMS1565974
doi:
Substances chimiques
Narcotic Antagonists
0
Buprenorphine
40D3SCR4GZ
Naltrexone
5S6W795CQM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
266-272Subventions
Organisme : NIAAA NIH HHS
ID : R01 AA027782
Pays : United States
Références
Health Aff (Millwood). 2019 Dec;38(12):1968-1970
pubmed: 31794296
J Subst Abuse Treat. 2017 Jan;72:48-55
pubmed: 27693108
N Engl J Med. 2016 Dec 8;375(23):2213-2215
pubmed: 27959694
Ann N Y Acad Sci. 2001 Jun;937:1-26
pubmed: 11458532
J Psychoactive Drugs. 2017 Sep-Oct;49(4):352-361
pubmed: 28657823
Int J Drug Policy. 2018 Jul;57:104-110
pubmed: 29715589
J Addict Med. 2014 Sep-Oct;8(5):315-26
pubmed: 25221984
Int J Methods Psychiatr Res. 2008 Jun;17 Suppl 1:S39-44
pubmed: 18543361
Health Aff (Millwood). 2019 Jan;38(1):14-23
pubmed: 30615514
N Engl J Med. 2016 Jan 28;374(4):363-71
pubmed: 26816013
JAMA. 2014 Apr 9;311(14):1393-4
pubmed: 24577059
Br J Pain. 2012 Feb;6(1):11-6
pubmed: 26516461
J Stud Alcohol Drugs. 2013 Mar;74(2):258-65
pubmed: 23384373
JAMA Psychiatry. 2017 Dec 1;74(12):1197-1205
pubmed: 29049469
Community Ment Health J. 2018 Jul;54(5):571-577
pubmed: 29302767
J Subst Abuse Treat. 2013 May-Jun;44(5):473-80
pubmed: 23217610
J Psychoactive Drugs. 2010 Dec;42(4):425-33
pubmed: 21305907
Subst Use Misuse. 2018 Jan 28;53(2):330-333
pubmed: 28961017
Eur Addict Res. 2012;18(1):1-11
pubmed: 21997500
Addiction. 1998 Jan;93(1):73-92
pubmed: 9624713
J Drug Issues. 2016 Jan 1;46(1):51-63
pubmed: 26834279
Addict Behav. 2007 Apr;32(4):803-18
pubmed: 16843612
Psychiatr Serv. 2014 Feb 1;65(2):158-70
pubmed: 24247147
Am J Addict. 2008 Sep-Oct;17(5):396-401
pubmed: 18770082
J Addict Med. 2014 Sep-Oct;8(5):345-50
pubmed: 25072677
Psychiatr Serv. 2014 Feb 1;65(2):146-57
pubmed: 24248468
JAMA. 2008 Dec 10;300(22):2613-20
pubmed: 19066381
J Subst Abuse Treat. 2007 Mar;32(2):207-15
pubmed: 17306729
Lancet. 2018 Jan 27;391(10118):309-318
pubmed: 29150198
J Stud Alcohol Drugs. 2015 Jan;76(1):143-51
pubmed: 25486403
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Addiction. 2012 May;107(5):973-82
pubmed: 22151478
Subst Abuse Treat Prev Policy. 2015 Mar 28;10:13
pubmed: 25884206
Med Care. 2018 Jun;56(6):505-509
pubmed: 29668645
Drug Alcohol Depend. 2011 May 1;115(1-2):23-9
pubmed: 21126830
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
Psychiatr Serv. 2014 Oct;65(10):1269-72
pubmed: 25270497
J Subst Abuse Treat. 1998 Jan-Feb;15(1):7-17
pubmed: 9534122
Curr Psychiatry Rep. 2017 Jun;19(6):35
pubmed: 28526967
Subst Abus. 2012;33(1):9-18
pubmed: 22263709
J Addict Med. 2015 Sep-Oct;9(5):358-67
pubmed: 26406300
Am J Community Psychol. 2013 Dec;52(3-4):406-11
pubmed: 24081318
Lancet. 2011 Apr 30;377(9776):1506-13
pubmed: 21529928
Mol Psychiatry. 2019 Dec;24(12):1868-1883
pubmed: 29934549
Addict Behav. 2019 Mar;90:222-228
pubmed: 30447514
Subst Use Misuse. 2008;43(12-13):1971-86
pubmed: 19016174
Am J Addict. 2012 Jan-Feb;21(1):55-62
pubmed: 22211347
Am J Public Health. 2006 Oct;96(10):1727-9
pubmed: 17008561
Lancet. 2018 Jan 27;391(10118):285-287
pubmed: 29150199
Subst Abus. 2019;40(4):459-465
pubmed: 31550201
Addiction. 2011 Jan;106(1):32-51
pubmed: 21054613
Addict Res Theory. 2019;27(5):373-382
pubmed: 31213965
J Addict Dis. 2012;31(3):207-25
pubmed: 22873183
AMA J Ethics. 2017 Sep 1;19(9):922-930
pubmed: 28905733
Drug Alcohol Depend. 2016 May 1;162:190-8
pubmed: 27012435
Annu Rev Biochem. 2018 Jun 20;87:897-919
pubmed: 29925258
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242
pubmed: 29779547
J Psychoactive Drugs. 2015 Jan-Mar;47(1):80-90
pubmed: 25715076
Drug Alcohol Depend. 2015 Dec 1;157:112-20
pubmed: 26507172
Psychiatr Serv. 2014 Mar 1;65(3):295-300
pubmed: 24141911
Subst Abuse. 2017 Mar 23;11:1178221816685087
pubmed: 28469424
Am J Addict. 2010 Jan-Feb;19(1):73-88
pubmed: 20132124
J Subst Abuse Treat. 2015 Jan;48(1):112-6
pubmed: 25205666